NAION Risk Higher in Patients on GLP-1 Drugs.

The article examines the heightened risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with Glucagon-like peptide-1 (GLP-1) receptor agonists like Ozempic and Mounjaro, revealing a 3.24-fold increased likelihood among users. It discusses the significant impact on vision health in diabetic patients due to these medications, emphasizing the need for cautious prescribing and monitoring to mitigate potential vision-related complications.